Indivior Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is

Indivior Pharmaceuticals, Inc. Stock at a Glance

Indivior Pharmaceuticals, Inc. (INDV) is currently trading at $38.48 with a market capitalization of $4.5B. The trailing P/E ratio stands at 19.73x, with a forward P/E of 9.82x. The 52-week range spans from $13.45 to $41.00; the current price is 6.1% below the yearly high. Year-over-year revenue growth stands at +19.2%. The net profit margin stands at 19.53%.

💰 Dividend

Indivior Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Indivior Pharmaceuticals, Inc. (INDV) on consensus: None. The average price target is $51.50, implying +33.84% from the current price. Analyst price targets range from $48.00 to $59.00.

Indivior Pharmaceuticals, Inc.: The Investment Case in Detail

Indivior Pharmaceuticals, Inc. (INDV) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 19.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 82% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 84.96%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Short interest sits at 12.72% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The forward P/E of 9.82x is meaningfully below the trailing 19.73x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 90.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
• The analyst consensus price target implies 33.84% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (12.72%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Indivior Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.